OR WAIT null SECS
A Yale School of Medicine study reveals that the high prevalence of the hepatitis C virus (HCV) among injection drug users may be partly due to the resilience of the virus in certain types of syringes. The study, which could open new avenues in preventing the spread of HCV, was the focus of a presentation at the 17th Conference of Retroviruses and Opportunistic Infections held Feb. 19.
This is believed to be the first study establishing the survival of HCV in contaminated syringes and the duration of potential infectiousness. HCV is transmitted through blood-to-blood contact. There is currently no vaccine against HCV, and treatments are problematic because of limited efficacy, high cost and side effects. Untreated, HCV can cause severe liver disease and even death. HCV infection from people sharing contaminated syringes is one of the most common and predictable consequences of injection drug use.
The Yale team simulated the most common scenarios of injection drug use in order to measure the longevity of the residual virus-blood mixture left in syringes after injection. After loading blood spiked with HCV into various syringes and depressing their plungers, researchers tested the residual blood for the presence of infective HCV immediately and after storage for up nine weeks.
They observed a prolonged survival of HCV infection at all storage temperatures, with viable amounts measured even at nine weeks in tuberculin syringes that have detachable needles. They observed far less viable HCV in insulin syringes with attached needles.
“This tells us that syringes with detachable needles are the most dangerous in terms of potential HCV infection, because they are far more likely to transmit a surviving virus,” said lead author Elijah Paintsil, MD, assistant professor of pediatrics and pharmacology at Yale School of Medicine.
The finding of prolonged HCV survival in detachable-needle syringes has greatest implication outside of the Untied States, where use of these syringes is more common. But it also has major health implications for cities and towns everywhere, including the U.S., that offer needle-exchange programs. “These programs often stress the importance of providing injection drug users with syringes that meet their needs,” Paintsil said. “Our findings suggest that if the goal is to reduce HCV transmission, these programs should discourage use of detachable-needle syringes.”
Other authors are Huijie He, Christopher Peters, Brett D. Lindenbach and Robert Heimer of Yale School of Medicine. This study was funded by grants from the National Institutes of Health, including a Clinical Translational Science Award (CTSA) Grant from the National Center for Research Resources.